This inventor holds 3 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent. Top assignee: Lupin, Inc.. Active years: 2015-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2015-2019
Title: Santosh Madhukar Jachak: Innovator in CRAC Modulation
Introduction
Santosh Madhukar Jachak is a notable inventor based in Maharashtra, India. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that modulate CRAC (Calcium Release-Activated Calcium) channels. With a total of 3 patents to his name, Jachak is recognized for his innovative approaches to treating various diseases and disorders.
Latest Patents
One of Jachak's latest patents focuses on "Oxazoline and isoxazoline derivatives as CRAC modulators." This invention relates to compounds of Formula (I) and outlines processes for their preparation. These compounds are useful for treating, preventing, and managing diseases, disorders, syndromes, or conditions associated with the modulation of CRAC. The patent further details methods for lessening the impact of these conditions, showcasing Jachak's commitment to advancing medical science.
Career Highlights
Santosh Madhukar Jachak is currently associated with Lupin, Inc., a prominent player in the pharmaceutical industry. His work at Lupin has allowed him to focus on innovative research and development, contributing to the company's mission of improving healthcare through advanced therapeutic solutions.
Collaborations
Jachak has collaborated with several talented individuals in his field, including Nageswara Rao Irlapati and Gokul Keruji Deshmukh. These collaborations have fostered a creative environment that encourages the exchange of ideas and enhances the development of new inventions.
Conclusion
Santosh Madhukar Jachak is a distinguished inventor whose work in CRAC modulation has the potential to impact the treatment of various medical conditions. His dedication to innovation and collaboration continues to drive advancements in pharmaceutical research.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile